IART
HealthcareIntegra LifeSciences Holdings Corporation
Key Drivers
- Margin Recovery
- Debt Overhang
- Cash Pressure
AIAI Summary
IART has shifted from a recall-driven survival story to a turnaround story, but the investment now hinges on proving that recent operating profit and improved liquidity can translate into durable free cash flow before debt burden and regulatory/execution risks erode the recovery.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Recovery
- •Debt Overhang
- •Cash Pressure
IART's operations improved materially in 2026-03-31 with higher margins and a return to operating profit, but heavy debt, weak net income, and negative free cash flow still limit the investment case.
Price Behavior
Key Price Behavior Insights:
- •Higher-Low Trend
- •Quick Rebound
- •Range Resistance
IART has trended steadily higher over the last month with a series of higher lows and a quick rebound above $18, but it still needs to clear $18.74-$18.76 to confirm upside momentum.
Sharp bounce after testing $17.89 on 2026-07-01 showed buyers defending the range
Sentiment & News
Key News Insights:
- •Value + momentum
- •Leadership changes
- •Regulatory repair
IART is being re-rated as a value-and-momentum name, but recent volatility and FDA-related execution issues keep the stock tied to progress on regulatory control, leadership, and operational fixes.
The stock's upside now depends on management proving sustained operational discipline and stronger regulatory oversight, which could rebuild investor confidence after past setbacks
Similar Companies in Healthcare
Other companies in the same sector with AI ratings